KLKristen N. Lee

Kristen N. Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristen N. Lee has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene therapy for metachromatic leukodystrophy: Compassionate use experience with atidarsagene autotemcel in the United States

    by Paul Orchard, Amitha Ananth, Jennifer Braun, Julie B. Eisengart, Ashish O. Gupta, Kristen Lee, Troy C. Lund, Saima Kayani, Nishitha R. Pillai, Ami J. Shah, et al.

    Background: Atidarsagene autotemcel (arsa-cel) is an ex vivo, lentiviral, autologous, hematopoietic stem cell–based gene therapy approved for the treatment of children with early-onset metachromatic leukodystrophy (MLD). This case series describes early experience with arsa-cel treatment in the United States and provides information on variable paths to identification and diagnosis of patients with MLD. Methods: Prior to approval by the US Food and Drug Administration, five patients classified as having early-onset MLD were treated with arsa-cel on a single-patient compassionate use basis at the University of Minnesota. Results: Two patients with presymptomatic late-infantile MLD were identified because of older siblings with MLD. Three patients were identified because of gallbladder disease, cranial neuropathy, or motor delays. All patients achieved hematologic recovery, and leukocyte arylsulfatase A activity increased to normal or above-normal levels within 30 days posttreatment. After 24 to 48 months (median, 36 months) of follow-up, the three patients who were presymptomatic at the time of treatment were independently ambulatory at last assessment. The two patients with early symptomatic early-juvenile MLD experienced cognitive and neurologic deterioration. Conclusion: This case series provides examples of the variety of clinical presentations in patients with MLD and emphasizes the importance of prompt diagnosis and referral of patients with early-onset MLD to provide the best opportunity to achieve optimal outcomes.

  • Open Access

    Hyperthyroidism-Associated Metabolic Decompensation in Maple Syrup Urine Disease

    by Megan Anne Harrison, Sruchika Sabu, Mark Dulchavsky, Rebecca Patterson, Elizabeth Sandberg, Kristen Lee

    BackgroundMaple syrup urine disease (MSUD) is an inherited disorder of branched-chain amino acid metabolism in which metabolic decompensation is commonly triggered by catabolic stress. Hyperthyroidism has rarely been reported as a precipitant of hyperleucinosis in patients with MSUD, with only a single prior case identified in the literature.Case PresentationA 21-year-old man with classic MSUD and previously stable metabolic control developed persistent hyperleucinosis despite adherence to typical sick-day management and without an easily identifiable trigger. Following hospital admission for refractory hyperleucinosis, evaluation revealed thyrotoxicosis with suppressed thyroid-stimulating hormone and elevated free thyroxine. Further investigation demonstrated positive thyroid peroxidase antibodies and findings consistent with Hashitoxicosis secondary to Hashimoto’s thyroiditis. Because standard therapies for thyroiditis-associated thyrotoxicosis posed challenges in the setting of MSUD, treatment was initiated with cholestyramine and propranolol. Following treatment of thyrotoxicosis and continued metabolic support, plasma leucine concentrations declined rapidly and normalized after discharge. The patient subsequently transitioned to hypothyroidism and required levothyroxine replacement therapy.ConclusionThis case highlights thyrotoxicosis due to Hashimoto’s thyroiditis as a potentially underrecognized trigger of metabolic decompensation in MSUD and supports consideration of thyroid disease in patients with unexplained metabolic instability.

  • Open Access

    Trisomy 5p: Long Recognized, Rarely Published‐ Three New Cases and Review of the Literature

    by Gabriela J. Kim, Kristen N. Lee, Amanda B. Pritchard

    Complete trisomy 5p is a rare chromosomal disorder caused by a duplication of the short arm of chromosome 5. Current data suggest that complete trisomy 5p presents as a distinct clinical syndrome including but not limited to seizures, developmental delays, facial dysmorphisms, failure to thrive, and recurrent respiratory infections. Given the rarity of this disorder, information regarding its presentation comes from a limited number of case studies. In this study, we present three new cases of complete trisomy 5p and compare these cases to the literature. With the addition of these three cases, there are 15 cases of complete trisomy 5p reported in the literature to date. This work reviews common clinical features of this disorder, including neonatal hypotonia, talipes equinovarus, seizures, macrocephaly, and abnormal ears. Suggested clinical evaluations and other less common features are also discussed.

  • Open Access

    Genetics Evaluation Outcomes From an Academic Multidisciplinary Atypical Diabetes Program

    by Colby L Chase, Marie-Louise Accardo, Veronica Greve, Elizabeth G Ames, Shane C Quinonez, Anthony Scott, Lauren Hipp, Jenna Damon, Wendy R Uhlmann, David T Broome, et al.

    Context: Rare monogenic conditions that predispose to diabetes can be misdiagnosed due to phenotypic overlap with more common conditions. Misdiagnosis can lead to ineffective, over-, or under-treatment. Specific genetic mechanisms can direct more precise treatment and facilitate clinical trial options. Recognition of characteristics of these conditions is necessary to facilitate high-yield referrals to genetics providers in order to improve diagnosis and treatment. Objective: Highlight clinical characteristics and diagnostic outcomes of patients undergoing genetics evaluation through a multidisciplinary Atypical Diabetes Program. Design, Setting, and Patients: Retrospective cohort review was completed for 87 patients referred to genetics from endocrinologists associated with the multidisciplinary Atypical Diabetes Program at a tertiary academic medical center between September 2019 and October 2022. Main Outcome Measure: Description of clinical characteristics of patients with a diagnostic or uncertain clinical genetic test result, as well as proportion of patients with these results. Results: Six patients (8.8%) had a pathogenic variant confirming diagnosis of lipodystrophy (4), monogenic diabetes (1), or monogenic obesity (1). Fifteen (22.0%) had a variant of uncertain significance, 5 of which correlated with their clinical features. As a result of genetics evaluation, all with a confirmed diagnosis had more precise treatment implemented and/or the opportunity to enroll in a clinical trial. Conclusion: Identification of rare genetic conditions predisposing to diabetes, enabled here through multidisciplinary genetics and endocrinology collaboration as part of the Atypical Diabetes Program, ultimately improves patient care. Endocrinologist attention to clinical features of these conditions is key to inform referral for genetics evaluation and testing.


  • Heterozygous CELF4 variants in the N-term region crucial for the RNA-binding activity lead to neurodevelopmental disorder and obesity

    by Ange-Line Bruel, Anneke T. Vulto-Vansilfhout, Frédéric Bilan, Gwenaël Le Guyader, Brigitte Gilbert-Dussardier, Xavier Le Guillou, Sophie Rondeau, Marlène Rio, Kristen N. Lee, Adelyn Beil, et al.

    RNA-binding proteins play a key role in post-transcriptional events, such as mRNA splicing, transport, stability, translation and decay. Dysregulation of RNA life can have dramatic consequences. CELF RNA-binding proteins appear to be essential during embryo development. In this study, we identified 15 patients with heterozygous missense or loss-of-function variants in the CELF4 gene by exome or genome sequencing. All variants affecting the N-terminus of the protein are essential and sufficient for the RNA-binding and splicing activity or RRM domains. Most patients presented with neurodevelopmental disorders including global developmental delay/intellectual disability (11/14), seizures (9/15) and overweight/obesity (10/14) that began in childhood. Clinical features are similar to the reported celf4-mouse mutant phenotype. This study highlights the essential role of CELF4 in development and its involvement as a novel etiology of neurodevelopmental disorders with obesity.


  • Open Access

    SAT080 Partnering With Medical Genetics To Provide Molecular Diagnosis In Atypical Diabetes

    by Maria Cristina Foss de Freitas, Colby Chase, Marie-Louise Henry, Adam Neidert, Goutham Narla, Wendy Uhlmann, Kristen Lee, Elif A Oral

    Disclosure: M.C. Foss de Freitas: Advisory Board Member; Self; PTC Therapeutics. C. Chase: None. M. Henry: None. A. Neidert: None. G. Narla: Advisory Board Member; Self; HERA Biolabs. Consulting Fee; Self; RAPPTA Therapeutics. Owner/Co-Owner; Self; RAPPTA Therapeutics. W. Uhlmann: None. K. Lee: None. E.A. Oral: Consulting Fee; Self; Regeneron Pharmaceuticals, Aegerion Pharmaceuticals, Ionis Pharmaceuticals Inc., Third Rock Ventures, Rejuvenate Inc. Grant Recipient; Self; Regeneron Pharmaceuticals, Aegerion Pharmaceuticals, Ionis Pharmaceuticals Inc., Novo Nordisk, Fractyl Laboratories, Rhythm Pharmaceuticals, GID Dynamics. Other; Self; Aegerion Pharmaceuticals. Uncovering genetic alterations causing rare and atypical phenotypes related to diabetes mellitus is becoming increasingly possible with next-generation sequencing. Our Atypical Diabetes Program formed a partnership with the Division of Genetic Medicine, creating a specialized Atypical Diabetes Genetics Clinic to provide genetic counseling and clinical diagnostic testing to patients with rare forms of diabetes and other metabolic diseases. Between 10/2019 and 07/2022, 82 patients were seen (42±12 years old; 76.3% female). Indications for referral varied: 32 (39.0%) were referred for suspected monogenic obesity, 31 (37.8%) for familial partial lipodystrophy (FPLD), 10 (12.2%) for MODY, 7 (8.5%) for familial dyslipidemia (FD), 4 (4.9%) for acquired partial lipodystrophy (APL), and 14 (17.1%) for other indications including concern for acquired generalized or partial lipodystrophy, adrenomyeloneuropathy, Alport syndrome, GIST, hemochromatosis, hypothyroidism and hypogonadism, immune dysregulation, laminopathy, multisystem health problems/congenital anomalies, Prader-Willi syndrome, renal glycosuria, and TAR syndrome. Fourteen (17.1%) patients were referred for multiple indications. Results from 64 patients who underwent genetic testing revealed 4 positive molecular findings (all in patients with lipodystrophy), confirming a pathogenic LMNA variant detected on research testing in one and revealing previously unknown molecular etiologies in three (a previously described likely pathogenic LMNA variant, a novel likely pathogenic PPARG variant, and a previously described homozygous pathogenic MFN2 variant). Clinical management was altered, aiming for a more personalized approach in patients with these new findings, and two are participating in clinical trials for their condition. Cascade testing for family members is now being pursued. Sixteen patients had variants of uncertain significance (VUS); in one of these cases, in silico prediction suggesting that the detected SH2B variant could be pathogenic has enabled enrollment in a Phase 2 study with setmelanotide. For other identified VUS, we are undertaking functional and biological studies using our novel translational platform, which was established to contribute evidence for possible variant reclassification. Deeper sequencing strategies are being considered for patients with negative results, with most of our patients participating in an NIH funded network study for Rare and Atypical Diabetes (RADIANT). In our early experience, partnering with a medical genetics team to provide molecular testing for rare forms of diabetes and other metabolic conditions can lead to precise molecular diagnosis and set the stage for deeper testing and improved clinical care while driving novel discovery work. Presentation: Saturday, June 17, 2023

  • Pearls & Oy-sters: Whole-Genome Sequencing in Critically Ill Neurologic Patient Leads to Diagnosis With Treatment Implications

    by Jonathan Read Gaillard, Zachary Whitt, Linda M. Selwa, David Harris, Kristen N. Lee

    Many adult patients with a history of seizures and global developmental delay do not have an identified etiology for their epilepsy. Rapid whole genome sequencing (rWGS) can be used to identify a genetic etiology in critically ill patients to provide actionable interventions. In this case, a 27-year-old patient with a history of epilepsy, global developmental delay, and intellectual disability presented with altered mental status and new abnormal movements. The patient acutely declined over the course of 24-48 hours of presentation, including nonconvulsive status epilepticus leading to intubation for airway protection, two episodes of ventricular tachycardia requiring synchronized cardioversion, and one episode of supraventricular tachycardia. The patient was found to be in metabolic crisis. Metabolic workup and rapid whole genome sequencing were sent. Patient was treated with 10% dextrose in normal saline and a mitochondrial cocktail. She received treatment with ammonia scavengers and hemodialysis with resolution of metabolic crisis. rWGS found a homozygous pathogenic variant in TANGO2 and a de novo pathogenic variant in KCNQ1, ultimately leading to creation of a metabolic emergency protocol and implantable cardioverter defibrillator (ICD) placement. This case highlights the use of rWGS in an acutely ill patient leading to actionable interventions. It also highlights the utility and importance of genetic sequencing in re-evaluation of adult neurologic patients.